Collegium Pharmaceutical
COLL
124 hedge funds and large institutions have $492M invested in Collegium Pharmaceutical in 2018 Q3 according to their latest regulatory filings, with 20 funds opening new positions, 47 increasing their positions, 35 reducing their positions, and 28 closing their positions.
546% more call options, than puts
Call options by funds: $6.12M | Put options by funds: $948K
34% more repeat investments, than reductions
Existing positions increased: 47 | Existing positions reduced: 35
6.66% more ownership
Funds ownership: 94.08% → 100.74% (+6.7%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
7% less funds holding
Funds holding: 133 → 124 (-9)
29% less first-time investments, than exits
New positions opened: 20 | Existing positions closed: 28
33% less capital invested
Capital invested by funds: $739M → $492M (-$247M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JGC
J. Goldman & Co
New York
|
+$23.1M |
| 2 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
+$15.5M |
| 3 |
Franklin Resources
San Mateo,
California
|
+$6.15M |
| 4 |
Janus Henderson Group
London,
United Kingdom
|
+$5.49M |
| 5 |
Massachusetts Financial Services
Boston,
Massachusetts
|
+$4.08M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CM
Castleark Management
Chicago,
Illinois
|
-$6.99M |
| 2 |
SPPAM
Summit Partners Public Asset Management
Boston,
Massachusetts
|
-$6.97M |
| 3 |
OCM
Osterweis Capital Management
San Francisco,
California
|
-$5.43M |
| 4 |
NIP
Nicholas Investment Partners
Rancho Santa Fe,
California
|
-$5M |
| 5 |
Millennium Management
New York
|
-$4M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
HMS
151
Hanseatic Management Services
Albuquerque,
New Mexico
| – | -$3K | -119 | Closed |
|
152
SEI Investments
Oaks,
Pennsylvania
| – | +$851 | +48 | New |
|
COLL Hedge Fund Activity: Q3 2018 in Review
124 of the 4,375 institutional investors tracked by Wall St. Rank reported a position in Collegium Pharmaceutical (COLL) for Q3 2018, worth a combined $492M — down 33% from $739M a quarter earlier.
Sellers outnumbered buyers: 28 funds closed out of COLL and 20 opened new positions — a net loss of 8 holders — while 35 trimmed existing stakes and 47 added.
The largest buyer was J. Goldman & Co, adding an estimated $23.1M. The largest seller was Castleark Management, exiting entirely with an estimated $6.99M sold.
- 124 institutional investors held Collegium Pharmaceutical (COLL) as of Q3 2018, down from 133 in Q2 2018.
- Funds reported $492M of Collegium Pharmaceutical stock for Q3 2018, down 33% quarter-over-quarter.
- 20 funds opened new Collegium Pharmaceutical positions in Q3 2018 and 28 closed out, a net change of -8 holders.
- The largest Collegium Pharmaceutical buyer in Q3 2018 was J. Goldman & Co, an estimated $23.1M added.
- The largest Collegium Pharmaceutical seller in Q3 2018 was Castleark Management, an estimated $6.99M sold.
Based on aggregated 13F filings for Q3 2018.